Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steffen Goletz

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Springerplus|July 27, 2013
What makes cancer stem cell markers different?Uwe Karsten, Steffen Goletz
Bioengineering (Basel, Switzerland)|September 28, 2017
Human Cell Line-Derived Monoclonal IgA Antibodies for Cancer ImmunotherapyFelix Hart, Antje Danielczyk, Steffen Goletz
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|July 12, 2005
What makes MUC1 a tumor antigen?Uwe Karsten, Silvia von Mensdorff-Pouilly, Steffen Goletz
Pathology, Research and Practice|April 20, 2010
Reactivity of a humanized antibody (hPankoMab) towards a tumor-related MUC1 epitope (TA-MUC1) with various human carcinomasXiao-Na Fan, Uwe Karsten, Steffen Goletz, et al.
Protein Expression and Purification|September 11, 2004
Simple separation of DNA in antibody purificationPeter Astrup Christensen, Antje Danielczyk, Renate Stahn, et al.
Applied and Environmental Microbiology|November 22, 2011
Preliminary safety evaluation of a new Bacteroides xylanisolvens isolatePhilippe Ulsemer, Kawe Toutounian, Jens Schmidt, et al.
Glycobiology|April 30, 2004
Binding patterns of DTR-specific antibodies reveal a glycosylation-conditioned tumor-specific epitope of the epithelial mucin (MUC1)Uwe Karsten, Nida Serttas, Hans Paulsen, et al.
Mabs|March 20, 2023
Generation of robust bispecific antibodies through fusion of single-domain antibodies on IgG scaffolds: a comprehensive comparison of formatsAndreas V Madsen, Peter Kristensen, Alexander K Buell, et al.
Frontiers in Bioengineering and Biotechnology|February 9, 2024
Design and engineering of bispecific antibodies: insights and practical considerationsAndreas V Madsen, Lasse E Pedersen, Peter Kristensen, et al.
Regulatory Toxicology and Pharmacology : RTP|November 17, 2011
Safety assessment of the commensal strain Bacteroides xylanisolvens DSM 23964Philippe Ulsemer, Kawe Toutounian, Jens Schmidt, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Springerplus|July 27, 2013
What makes cancer stem cell markers different?Uwe Karsten, Steffen Goletz
Bioengineering (Basel, Switzerland)|September 28, 2017
Human Cell Line-Derived Monoclonal IgA Antibodies for Cancer ImmunotherapyFelix Hart, Antje Danielczyk, Steffen Goletz
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|July 12, 2005
What makes MUC1 a tumor antigen?Uwe Karsten, Silvia von Mensdorff-Pouilly, Steffen Goletz
Pathology, Research and Practice|April 20, 2010
Reactivity of a humanized antibody (hPankoMab) towards a tumor-related MUC1 epitope (TA-MUC1) with various human carcinomasXiao-Na Fan, Uwe Karsten, Steffen Goletz, et al.
Protein Expression and Purification|September 11, 2004
Simple separation of DNA in antibody purificationPeter Astrup Christensen, Antje Danielczyk, Renate Stahn, et al.
Applied and Environmental Microbiology|November 22, 2011
Preliminary safety evaluation of a new Bacteroides xylanisolvens isolatePhilippe Ulsemer, Kawe Toutounian, Jens Schmidt, et al.
Glycobiology|April 30, 2004
Binding patterns of DTR-specific antibodies reveal a glycosylation-conditioned tumor-specific epitope of the epithelial mucin (MUC1)Uwe Karsten, Nida Serttas, Hans Paulsen, et al.
Mabs|March 20, 2023
Generation of robust bispecific antibodies through fusion of single-domain antibodies on IgG scaffolds: a comprehensive comparison of formatsAndreas V Madsen, Peter Kristensen, Alexander K Buell, et al.
Frontiers in Bioengineering and Biotechnology|February 9, 2024
Design and engineering of bispecific antibodies: insights and practical considerationsAndreas V Madsen, Lasse E Pedersen, Peter Kristensen, et al.
Regulatory Toxicology and Pharmacology : RTP|November 17, 2011
Safety assessment of the commensal strain Bacteroides xylanisolvens DSM 23964Philippe Ulsemer, Kawe Toutounian, Jens Schmidt, et al.
Pageof 6